ELUVIA™ Drug-eluting Stent Versus Zilver® PTX® Stent
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 524 participants.
Also called NCT02574481
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 524 participants
- Sponsor
- Registry
-
NCT02574481
-
- Other papers using this trial's data
- 24-Month Efficacy and Safety Results from Japanese Patients in the IMPERIAL Randomized Study of the Eluvia Drug-Eluting Stent and the Zilver PTX Drug-Coated Stent
- A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial
- Japanese Patients Treated in the IMPERIAL Randomized Trial Comparing Eluvia and Zilver PTX Stents
- Two-Year Efficacy and Safety Results from the IMPERIAL Randomized Study of the Eluvia Polymer-Coated Drug-Eluting Stent and the Zilver PTX Polymer-free Drug-Coated Stent
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Austria, Belgium, Canada, Germany, Japan, New Zealand
- Registry status
- Completed
Technical summary
Registry record NCT02574481. Randomized; single masking; primary purpose treatment. Start 2015-12 (actual); primary completion 2017-12-28 (actual). Results posted on 2019-01-07.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- ELUVIA™ Drug-eluting Stent Versus Zilver® PTX® Stent
- Acronym
- IMPERIAL
- Condition
- Atherosclerosis of Native Arteries of the Extremities
- Intervention (Device)
- ELUVIA (Stent Implantation)
- Intervention (Device)
- Zilver PTX (Stent Implantation)
- Lead sponsor
- Boston Scientific Corporation
Record details
- Record id
cardio:ct-nct02574481- Content hash
b496d501f00d7b879df8f56856933f1a1af4d433eb0e1756ef741ff6ce05397b